Alectinib: A novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance

Acta Pharmaceutica Sinica B

Volumn 5, Issue 1, 2015, Pages 34-37

  Song, Zilan ^a   Wang, Meining ^a   Zhang, Ao ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Alectinib; ALK mutations; Crizotinib; EML4 ALK; Non small cell lung cancer; Resistance; Tyrosine anaplastic lymphoma kinase

Indexed keywords

ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB;

ADVANCED CANCER; ALK GENE; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; EML4 GENE; GENE MUTATION; HUMAN; IC50; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOGENE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 84945189935     PISSN: 22113835     EISSN: 22113843     Source Type: Journal    
DOI: 10.1016/j.apsb.2014.12.007     Document Type: Review

References (21)

1. Morris S.W., Kirstein M.N., Valentine M.B., Dittmer K.G., Shapiro D.N., Saltman D.L., et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin[U+05F3]s lymphoma. Science 1994, 263:1281-1284.
2. Rikova K., Guo A.L., Zeng Q.F., Possemato A., Yu J., Haack H., et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007, 131:1190-1203.
3. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
4. Roskoski R. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. Pharmacol Res 2013, 68:68-94.
5. Shaw A.T., Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res 2011, 17:2081-2086.
6. Gridelli C., Peters S., Sgambato A., Casaluce F., Adjei A.A., Ciardiello F. ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev 2014, 40:300-306.
7. Cui J.J., Tran-Dubé M., Shen H., Nambu M., Kung P.P., Pairish M., et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 2011, 54:6342-6363.
8. Cui J.J., McTigue M., Kania R., Edwards M.P. Case history: Xalkori™ (crizotinib), a potent and selective dual inhibitor of mesenchymal epithelial transition (MET) and anaplastic lymphoma kinase (ALK) for cancer treatment. Ann Rep Med Chem 2013, 48:421-432.
9. Shaw A.T., Yeap B.Y., Solomon B.J., Riely G.J., Gainor J., Engelman J.A., et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011, 12:1004-1012.
10. Doebele R.C., Pilling A.B., Aisner D.L., Kutateladze T.G., Le A.T., Weickhardt A.J., et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012, 18:1472-1482.
11. Kinoshita K., Oikawa N., Tsukuda T. Anaplastic lymphoma kinase inhibitors for the treatment of ALK-positive cancers. Ann Rep Med Chem 2012, 47:281-293.
12. Choi Y.L., Soda M., Yamashita Y., Ueno T., Takashima J., Nakajima T., et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010, 363:1734-1739.
13. Ramalingam S., Khuri F.P. Second generation ALK inhibitors: filling the non 'MET' gap. Cancer Disc 2014, 4:634-636.
14. Wang W.C., Shiao H.Y., Lee C.C., Fung K.S., Hsieh H.P. Anaplastic lymphoma kinase (ALK) inhibitors: a review of design and discovery. Med Chem Commun 2014, 5:1266-1279.
15. Awad M.M., Shaw A.T. ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol 2014, 12:429-439.
16. Marsilje T.H., Pei W., Chen B., Lu W., Uno T., Jin Y., et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2, 4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem 2013, 56:5675-5690.
17. Shaw A.T., Kim D.W., Mehra R., Tan D.S., Felip E., Chow L.Q., et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014, 370:1189-1197.
18. Latif M., Saeed A., Kim S.H. Journey of the ALK-inhibitor CH5424802 to phase II clinical trial. Arch Pharm Res 2013, 36:1051-1054.
19. Kinoshita K., Kobayashi T., Asoh K., Furuichi N., Ito T., Kawada H., et al. 9-Substituted 6, 6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors. J Med Chem 2011, 54:6286-6294.
20. Sakamoto H., Tsukaguchi T., Hiroshima S., Kodama T., Kobayashi T., Fukami T.A., et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011, 19:679-690.
21. Seto T., Kiura K., Nishio M., Nakagawa K., Maemondo M., Inoue A., et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol 2013, 14:590-598.